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Abstract 
Altered protein kinase activity is a contributing factor in many diseases including 
most forms of human malignancies, and there is reason to believe that protein 
kinases will prove to be major drug targets in the treatment of cancer. Protein 
kinases mediate most of the signal transduction in eukaryotic cells, regulating 
cellular events such as transcription, metabolism, proliferation, cytoskeletal 
rearrangement, migration, differentiation and apoptosis. Protein 
phosphorylation also plays a critical role in intercellular communication during 
embryonic development, especially through activation of receptor tyrosine 
kinases (RTK:s). 
This study focuses on the Platelet-derived growth factor (PDGF) family, 
secreted molecules whose functions are to bind to, and activate, two structurally 
related RTK:s, PDGF receptor alpha and beta. To gain insight into the 
developmental role of PDGF-A and -C, three lines of mice were generated in 
which these genes were modified by gene targeting. 
As a common principle, PDGF-A and -C, secreted from epithelial cells, 
induced proliferation, and possibly migration, of mesenchymal progenitor cells 
expressing PDGF receptor alpha. 
Mice deficient for PDGF-A died perinatally and displayed defective lung 
development due to lack of alveolar formation. This phenotype was coupled to a 
loss of alveolar smooth muscle cells and reduced parenchymal elastin, resulting in 
a picture resembling emphysema. 
The sixth exon in PDGF-A is normally alternatively spliced, and, when 
present, it confers binding to extracellular matrix structures. The second line of 
mice generated carried a mutation in the sixth exon splice acceptor, so that only 
the short, freely diffusible form of PDGF-A was being produced. Analysis of 
these mice suggested overlapping functions for PDGF-A and -C, and also 
revealed that extracellular retention of PDGF-A is important for normal 
development of gastrointestinal villi. 
Depending on genetic background, PDGF-C negative mice died postnatally 
due to a cleft palate accompanied by moderate spina bifida. Interestingly, 
PDGF-A / PDGF-C double deficient mice were phenotypically indistinguishable 
from mice carrying a null mutation in PDGF receptor alpha. Taken together, 
the results of this study imply that PDGF-A and -C are the physiologically 
important ligands for PDGF receptor alpha during development. 
 
 
Keywords: platelet-derived growth factor, PDGF-A, PDGF-C, PDGF alpha receptor, 
extracellular retention,  gene targeting, mouse development, epithelial-mesenchymal 
interaction, lung, alveolar formation, spina bifida, gastrointestinal villus 
 
ISBN 91-628-5574-3
PDGF-A and -C: Essential Ligands for the PDGF Alpha Receptor 
 
List of publications 
 
This thesis is based on the following publications, referred to in the text by their 
Roman numerals. 
 
 
I.  PDGF-A signaling is a critical event in lung alveolar myofibroblast 
development and alveogenesis. 
Bostrom, H., Willetts, K., Pekny, M., Leveen, P., Lindahl, P., Hedstrand, 
H., Pekna, M., Hellstrom, M., Gebre-Medhin, S., Schalling, M., Nilsson, 
M., Kurland, S., Tornell, J., Heath, J. K. and Betsholtz, C. 
Cell 85, 863-873 (1996) 
 
II. PDGF-A / PDGF alpha-receptor signaling is required for lung growth and 
the formation of alveoli but not for early lung branching morphogenesis. 
Bostrom, H., Gritli-Linde, A., and Betsholtz, C. 
Dev. Dyn. 223(1):155-162 (2002) 
 
III.  PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. 
Li, X., Ponten, A., Aase, K., Karlsson, L., Abramsson, A., Uutela, M., 
Backstrom, G., Hellstrom, M., Bostrom, H., Li, H., Soriano, P., 
Betsholtz, C., Heldin, C.H., Alitalo, K., Ostman, A. and Eriksson, U. 
Nature Cell Biol. 2(5):302-9 (2000) 
 
IV.  PDGF-C and -A exert both overlapping and specific developmental 
functions through the PDGF alpha-receptor. 
Ding, H., Wu, X., Bostrom, H., Kim, I., Koh, G.Y., Soriano, P., 
Betsholtz, C., Tam, P.P.L. and Nagy, A. 
Manuscript (2003) 
 
V.  Mice engineered to produce only the short form of PDGF-A point to the 
importance of extracellular retention of growth factors. 
Bostrom, H., Ding, H., Bianconi, S., Nagy, A. and Betsholtz, C. 
Manuscript (2003) 
 
 
 
Reprints were made with permission from the publishers. 
H Boström 
 
Table of contents 
 
Abbreviations.......................................................................................................................... 8 
Introduction ........................................................................................................................... 9 
Protein kinases - major information bearing molecules .................................................................................. 9 
Altered protein tyrosine kinase activity and human disease .......................................................................... 11 
Platelet-derived growth factors - secreted molecules that activate 
two receptor tyrosine kinases................................................................................................. 17 
PDGF isoforms........................................................................................................................................... 18 
Extracellular retention of PDGF isoforms .............................................................................................. 22 
PDGF receptors .......................................................................................................................................... 23 
Expression of PDGF and PDGF receptors .................................................................................................. 27 
Developmental functions of PDGF - lessons from gene targeting in mice ............................. 31 
Gene targeting - methodological aspects ...................................................................................................... 31 
Platelet-derived growth factor mutants ........................................................................................................ 34 
Complex phenotypic alterations in PDGF-A knockout mice ................................................................. 34 
The importance of extracellular retention of PDGF-A ........................................................................... 38 
Mice deficient for PDGF-B display cardiac and vascular defects............................................................. 39 
Cell-type-specific ablation of PDGF-B by the creation of chimeric mice 
and conditional gene targeting............................................................................................................... 40 
PDGF-C negative mice show cleft palate and spina bifida...................................................................... 41 
PDGF receptor mutants.............................................................................................................................. 42 
Patterning of the somites and development of neural-crest-derived 
mesenchyme is dependent on PDGFRα ................................................................................................ 42 
PDGFR-β negative mice phenocopy PDGF-B knockouts...................................................................... 43 
Cell autonomous requirement for PDGF receptors revealed 
by chimeric analyses............................................................................................................................... 43 
Selective mutations in PDGF receptors suggest both overlapping and 
specific functions for RTK-activated signaling pathways ........................................................................ 44 
The generation of PDGF-A / PDGF-C double deficient mice provides 
an important piece in the PDGF puzzle ...................................................................................................... 47 
Critical PDGF ligand/receptor specificities in mouse development .............................................................. 48 
Analogous functions for PDGFs and their target cells.................................................................................. 49 
Summary and clinical perspective ......................................................................................... 51 
Acknowledgments................................................................................................................. 55 
References............................................................................................................................. 57 
 
PDGF-A and -C: Essential Ligands for the PDGF Alpha Receptor 
 
Abbreviations 
 
ABL   Abelson tyrosine kinase 
ApoE   apolipoprotein E 
ASMA  alpha smooth muscle actin 
ATP   adenosine triphosphate 
CSF1R colony stimulating factor 1 receptor (also called FMS) 
CUB domain found in complement, urchin-like EGF protein and 
bone morphogenetic protein-1 
E   embryonic day 
EGF   epidermal growth factor 
FGF   fibroblast growth factor 
GDNF  glial derived neurotrophic factor 
GIST   gastrointestinal stromal tumor 
Grb2   growth factor receptor bound protein 2 
FLT3   FMS-related tyrosine kinase 3 
KIT   stem cell factor receptor 
MAPK  mitogen-activated protein kinase 
MEN   multiple endocrine neoplasia 
Neo   neomycin (resistance gene) 
NGF   nerve growth factor 
P   postnatal day 
PDGF  platelet-derived growth factor 
PDGFR  PDGF receptor 
PI3K   phosphatidyl inositol 3’ kinase 
PLCγ   phospholipase C-gamma 
PlGF   placenta growth factor 
Ras-GAP  GTPase-activating protein for Ras 
RET   receptor for GDNF 
RTK   receptor tyrosine kinase 
SH2   src homology 2 domain 
SHP2   SH2 tyrosine phosphatase 2 
Sos1   son of sevenless homologue 1 
SPARC  secreted protein, acidic, and rich in cysteine 
STAT   signal transducers and activators of transcription 
TGFβ  transforming growth factor beta 
VEGF  vascular endothelial growth factor 
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Introduction 
 
“There is no rest for the messenger til the message is delivered” 
Joseph Conrad, The Rescue (1920) 
 
 
Protein kinases - major information bearing molecules 
In this thesis, the developmental role of two members of the Platelet-Derived 
Growth Factor (PDGF) family, PDGF-A and -C, has been studied by the 
creation of loss-of-function mutations through gene targeting in mice. 
The action of PDGF is mediated via two receptor tyrosine kinases, members 
of the larger gene superfamily of protein kinases. In an attempt to place PDGF 
within its evolutionary context, one may ask: what is the function of protein 
kinases in general? 
Protein phosphorylation (and dephosphorylation) is the most prevalent 
reversible covalent modification of proteins in the human cell, and this 
mechanism provides a cellular infrastructure for the sensing of extracellular 
signals and the coordination of intracellular events such as transcription, 
metabolism, proliferation, cytoskeletal rearrangement, migration, differentiation 
and apoptosis. 
While dephosphorylation is performed by phosphatases, protein kinases 
phosphorylate proteins by transferring phosphoryl groups from ATP to specific 
amino acid residues. 
For a long time, protein kinases where presumed to exist exclusively in 
eukaryotic cells, but recent biomedical research including the near-complete 
sequencing of several genomes has shown that the picture is more complex and 
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that protein phosphorylation is a major mechanism for transducing information 
in all living organisms (Kennelly and Potts, 1996). However, clear trends in the 
distribution of kinase subgroups can be seen, which imply divergent functions. 
In bacteria, the most common protein kinases are protein-histidine kinases, 
while the Hanks-type (formerly called “eukaryotic”) protein kinases can be 
subdivided according to their ability to phosphorylate either serine/threonine or 
tyrosine residues. Hanks-type protein kinases are uncommon in prokaryotes, but 
represent one of the largest protein superfamilies in mammals, constituting about 
1.7% of all human genes. In total, 518 protein kinase genes have been identified 
in the human genome (Manning et al., 2002b). 
 
Group Yeast kinases 
Fly 
kinases 
Worm 
kinases 
Human 
kinases 
Serine/Threonine 
kinase 115 168 302 340 
Tyrosine 
kinase 0 32 90 90 
Tyrosine 
kinase-like 0 17 15 43 
RGC & Atypical 15 23 47 45 
Total 130 240 454 518 
 
Table 1. Protein kinase distribution by major groups. Modified 
from (Manning et al., 2002b). 
 
 
Interestingly, when comparing the distribution of kinase subgroups in 
different eukaryotes, it is evident that although serine/threonine protein kinases 
are abundant already in primitive organisms such as brewer’s yeast (Saccharomyces 
cerevisiae), tyrosine kinases seem to be largely restricted to multicellular 
organisms (Table 1).  
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Tyrosine kinases, in turn, form two major groups due to their subcellular 
location, cytoplasmic and receptor tyrosine kinases (RTKs) (Fig. 1A). Given the 
assumption that tyrosine kinase signaling is important for intercellular 
communication in the developing multicellular organism, RTKs are especially 
interesting since they possess an extracellular domain that can respond to 
external stimuli, in addition to an intracellular tyrosine kinase domain (Fig. 1B). 
Indeed, until recently RTKs were presumed to exist only in metazoans, but 
now the first receptor tyrosine kinase in a choanoflagellate, a unicellular 
organism suspected to be closely related to animals, has been identified (King 
and Carroll, 2001). This suggests that the evolution of receptor tyrosine kinases 
may have been a prerequisite for the emergence of the animal kingdom, with the 
increased coordination of cellular events that is necessary when multiple cells 
have to harmonize their collective destinies in the building of tissues and organs. 
There is now ample evidence that cell signaling by RTKs plays an important 
role in the control of most fundamental cellular processes in the metazoans 
(reviewed in Hunter, 2000; Schlessinger, 2000). 
 
Altered protein tyrosine kinase activity and human disease 
Tyrosine kinases are interesting not only from the viewpoint of developmental 
biology, but also highly relevant from a medical perspective. If tyrosine kinases 
are fundamental for normal cell signaling, what happens when those signals 
are disturbed? 
In principle, mutations in TKs can lead to either diminished or increased 
activation of downstream signaling pathways. 
 
Inactivation of TKs has been demonstrated to be a causative factor in several 
developmental disorders, for instance severe combined immunodeficiency disease  
PDGF-A and -C: Essential Ligands for the PDGF Alpha Receptor 
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Figure 1. The human tyrosine kinases. A) Phylogenetic tree of cytoplasmic and receptor 
tyrosine kinases. B) Structure of receptor tyrosine kinases. Modified with permission from 
www.cellsignal.com 
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(mutations in JAK3 and ZAP70), retinal dystrophy (MER), hereditary 
lymphedema (VEGFR3), hereditary agammaglobulinemia (BTK) and 
Hirschsprung’s disease (RET) (reviewed in Hunter, 2002). New drugs targeted 
to potentiate TK signaling may provide relief for these and other disorders. 
Tissue regeneration is another area in which activation of primarily RTKs 
could be of major importance, by inducing resting progenitor cells to proliferate. 
Clinical trials with glial derived neurotrophic factor (GDNF) treatment for 
Parkinson’s and nerve growth factor (NGF) for Alzheimer’s diseases are under 
way (Maimone et al., 2001). Therapeutic angiogenesis by vascular endothelial 
growth factor (VEGF) gene transfer shows promising results on peripheral 
arterial disease and ischemic heart disease (Morishita, 2002), even if combination 
therapy with other factors, such as PDGF-BB, are likely to be necessary to ensure 
long-term functionality of the newly formed blood vessels (Blau and Banfi, 
2001). 
 
The GDNF receptor tyrosine kinase RET is a good example of the duality of TK 
dysregulation. As mentioned above, inactivation of RET causes Hirschsprung’s 
disease, a congenital absence of enteric neurons in the hindgut. Germline 
mutations that lead to constitutive activation of RET, on the other hand, is the 
cause for multiple endocrine neoplasia type 2 (MEN 2), an inherited cancer 
syndrome (Jhiang, 2000). 
Deregulated (autonomous) cell growth is a hallmark of all benign and 
malignant neoplasms. In 1980, it was demonstrated that v-src, the protein 
responsible for malignant transformation in Rous sarcoma virus, was a tyrosine 
kinase (Collett et al., 1980; Hunter and Sefton, 1980), and  in 1983 another 
viral oncogene, v-sis, was shown to be highly homologous to a known mitogen, 
the PDGF receptor tyrosine kinase ligand PDGF-B (Devare et al., 1983; 
PDGF-A and -C: Essential Ligands for the PDGF Alpha Receptor 
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Doolittle et al., 1983; Waterfield et al., 1983). This historical finding gave rise to 
the idea that so called “oncogenes” in truth were mutated versions of normal 
growth-promoting genes. Further support for this hypothesis came when it was 
discovered that a constitutively active truncated EGF-receptor gene, v-erbB, was 
responsible for the transforming ability of the avian erythroblastosis virus 
(Downward et al., 1984; Ullrich et al., 1984). 
Today, it is a well-established dogma that cancer occurs when mutations in 
the genome of a cell lead to a selective growth advantage, and more than 30 
recessive tumor suppressor genes and 100 dominant oncogenes have been 
identified (Futreal et al., 2001). Tyrosine kinases form the largest group of 
dominant oncogenes with structural homology, and at least 45 group members 
have been implied in human cancers (reviewed in Blume-Jensen and Hunter, 
2001). 
 
From this perspective, it is not surprising that academic scientists and 
pharmaceutical companies have identified protein kinases as major drug targets. 
A landmark event in this work occurred in 2001, when the first specific protein-
kinase inhibitor, imatinib mesylate (Glivec®) was approved for clinical use. 
Imatinib was developed to target the mutated Abelson tyrosine kinase (BCR-
ABL) found in Philadelphia-chromosome positive chronic myelogenous 
leukemia (CML), and clinical trials demonstrated surprisingly positive results, 
especially in late chronic phase CML (Kantarjian et al., 2002). 
Imatinib is an ATP competitive inhibitor, and in addition to the effect on ABL, 
it also inhibits c-KIT and the PDGF receptors. c-KIT (and PDGF receptor 
alpha) mutations are causative factors in gastrointestinal stromal tumors (GIST), 
and rearrangement of the PDGF beta receptor by fusion with the TEL gene is 
responsible for a subgroup of myeloproliferative diseases. Preliminary studies 
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indicate that imatinib is efficient also in treating these disorders (see Capdeville 
et al., 2002, for a review on the development and clinical trials of imatinib 
mesylate). 
Imatinib was the first specific protein-kinase inhibitor to be developed, but it 
certainly will not be the last. In fact, protein kinases have now become the 
second most important group of drug targets after G-protein-coupled receptors. 
While most drugs are aimed at various forms of cancer, other interesting 
therapeutic areas exist and protein-kinase inhibitors may prove to be useful 
immunosuppressants, as well as anti-fibrotic and anti-inflammatory drugs 
(reviewed in Cohen, 2002). 
 
To summarize, modulation of protein kinase activity will likely emerge as an 
important clinical paradigm in the following decades, with a range of drugs 
available for the treatment of cancers and other diseases. In order to rationally 
develop efficient compounds, and use them with good clinical results, we need to 
increase our understanding of the fundamental biology of protein kinase 
signaling. The focus of this thesis - studies on the developmental role of platelet-
derived growth factors - is one such example. 
PDGF-A and -C: Essential Ligands for the PDGF Alpha Receptor 
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Platelet-derived growth factors - secreted molecules that 
activate two receptor tyrosine kinases 
 
“I hold it probable that in the germ cells there exist fine internal differences 
which predetermine the subsequent transformation to a determinant 
substance; not differences which are mere potencies present in the germ cells, 
but actual material differences so fine that we have not as yet been able to 
demonstrate them.” 
Rudolf Virchow, Die Cellularpathologie (1858) 
 
 
The history of platelet-derived growth factor (PDGF) dates back about thirty 
years, when Balk observed that serum was more efficient than plasma in 
promoting proliferation of fibroblasts in vitro (Balk, 1971). Subsequently, this 
growth promoting activity was located to platelets (Kohler and Lipton, 1974; 
Ross et al., 1974), and around 1980, PDGF was purified from human 
thrombocytes (Antoniades et al., 1979; Heldin et al., 1979; Raines and Ross, 
1982). Since this discovery, several reports have shown that PDGF by no means 
is restricted to the platelets, but rather is produced in a large number of different 
cell types. 
The structural and functional properties of PDGF and PDGF receptors in 
health and disease have been extensively studied over the last two decades (for a 
detailed review, see Heldin and Westermark, 1999). It is not my intention to 
give a comprehensive summary here, but rather focus on aspects of PDGF 
biology that are important as a background to the present study. 
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PDGF isoforms 
Platelet-derived growth factor is a family of five identified disulfide-linked homo- 
and heterodimers (PDGF-AA, -BB, -AB, -CC and -DD) that are encoded by 
four genes (PDGF A-D). PDGF-C and -D were discovered only recently (Paper 
III; Bergsten et al., 2001; Gilbertson et al., 2001; LaRochelle et al., 2001), so 
most studies have been performed on PDGF-A and -B. 
 
PDGF-A and -B are synthesized as precursor molecules that undergo proteolytic 
processing. In the mature parts of approximately 100 amino acid residues, eight 
cysteines are perfectly conserved (Betsholtz et al., 1986). The C- and -D chains 
of PDGF show the same eight cysteine motif, but three additional amino acids 
are inserted in the most conserved region (Paper III; Bergsten et al., 2001; 
Gilbertson et al., 2001; Heldin et al., 2002; LaRochelle et al., 2001). 
A similar spacing between cysteine residues is seen also in the vascular 
endothelial growth factor (VEGF) family (reviewed in (Veikkola and Alitalo, 
1999), and this suggests that the PDGFs and VEGFs have evolved by 
evolutionary divergence from a common ancestral gene (Fig. 2; Bergsten et al., 
2001). 
 
The crystal structure of PDGF-BB has been determined (Oefner et al., 1992), 
and this has revealed the involvement of the conserved cysteines in inter- and 
intrachain disulfide bonds. The second and fourth cysteines are responsible for 
interchain dimerization, which arranges the dimer in an antiparallell manner. 
The remaining six residues are engaged in a tight cystine knot structure in the 
PDGF monomer. This simple yet robust structure places PDGF/VEGF in a 
larger Cystine Knot superfamily, since a similar knot exists also in the nerve 
growth factor (NGF), transforming growth factor beta (TGFβ) and glycoprotein 
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hormone (GPH) families. Apart from the cystine knot, these protein families 
lack sequence similarity, and it is possible that this represents an example of 
evolutionary convergence (rather than divergence), since the formation of a 
cystine knot is an efficient mechanism to create loops in a polypeptide chain 
(Hearn and Gomme, 2000). 
 
 
 
 
Figure 2. Evolutionary relationships in the PDGF / VEGF family. 
 
 
The three loops in PDGF-B connect two pairs of β-strands. In PDGF-BB, loop 
one and three from one monomer, and loop two from the other are exposed on 
each side of the dimer (Oefner et al., 1992). These loops in PDGF-A and -B are 
the receptor binding epitopes (Andersson et al., 1995; Clements et al., 1991; 
Fenstermaker et al., 1993; LaRochelle et al., 1992; Ostman et al., 1993). While 
VEGF-A
PlGF
VEGF-B
VEGF-C
VEGF-D
PDGF-C
PDGF-D
PDGF-A
PDGF-B
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it is likely that the corresponding sequences in PDGF-C and -D have the same 
function, this remains to be shown. 
 
The genomic organization of the PDGF family genes is depicted in Fig. 3 
(modified from Uutela et al., 2001). 
The genes for PDGF-A and -B are located on human chromosomes 7 and 22 
(Betsholtz et al., 1986; Dalla-Favera et al., 1982). PDGF-A and -B are closely 
structurally related, showing approximately 60% amino acid identity in the 
mature proteins, encoded mainly by exons 4 and 5 (Betsholtz et al., 1986). Exon 
1 encodes a hydrophobic signal sequence that together with exons 2 and 3 is 
removed during intracellular processing. Exon 7 is largely noncoding, and exon 6 
in both PDGF-A and -B encodes a basic carboxyterminal sequence. In PDGF-B, 
the exon6-encoded sequence may be proteolytically removed, whereas PDGF-A 
exists in two splice variants, with or without this basic sequence (further 
discussed under “Extracellular retention”). 
 
The genes for PDGF-C and -D, located on human chromosomes 4 and 11 
(Uutela et al., 2001), show only about 20% sequence identity with PDGF-A and 
-B in the PDGF core domain, but 50% amino acid identity with each other 
(Bergsten et al., 2001).  The PDGF core domain is encoded by the fifth and 
sixth exons in PDGF-C, and the sixth and seventh exons in PDGF-D. As in the 
“old” PDGFs, the first exon of PDGF-C and -D appears to represent a signal 
sequence. The second and third exons of PDGF-C and -D contain a sequence 
that is absent in all other PDGFs and VEGFs, but show similarity with the 
CUB-domain found in complement subcomponents C1r/C1s, urchin EGF-like 
protein and bone morphogenetic protein-1 (Bork, 1991). The function of this 
motif is unknown. It may have a regulatory function since it needs to be cleaved 
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off after secretion to render PDGF-CC and -DD active (Paper III; Bergsten et 
al., 2001; Gilbertson et al., 2001; LaRochelle et al., 2001). Putative proteolytic 
cleavage sites are marked with arrows in Fig. 3. 
 
 
 
Figure 3. Genomic organization of PDGF isoforms. Modified from (Uutela et al., 2001). 
 
 
 
Platelets and cells that express both PDGF-A and -B contain PDGF-AA, -BB 
and -AB dimers, with the major part being the PDGF-AB heterodimer 
(Hammacher et al., 1988a; Hammacher et al., 1988b; Hart et al., 1990). This 
indicates that the assembly of these PDGF dimers is a stochastic process. PDGF-
C and -D, on the other hand, have not been reported to form heterodimers. 
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Extracellular retention of PDGF isoforms 
The sixth exon in both PDGF-A and -B encodes a highly basic stretch of amino 
acids that was originally identified as a nuclear targeting signal (Lee et al., 1987; 
Maher et al., 1989), but later studies have shown that the probable biological 
function of this motif is to confer binding to extracellular matrix structures 
(Kelly et al., 1993; LaRochelle et al., 1991; Pollock and Richardson, 1992; 
Raines and Ross, 1992). While PDGF has been reported to bind to several 
extracellular matrix molecules such as SPARC (Raines et al., 1992), collagens 
(Somasundaram and Schuppan, 1996) and thrombospondin (Hogg et al., 1997), 
it is likely that the most important binding is that to negatively charged groups 
in heparan sulfate proteoglycans (Andersson et al., 1994; Feyzi et al., 1997; 
Lustig et al., 1996). 
 
PDGF-A exists in two isoforms due to alternative splicing of the sixth exon, thus 
producing one short, freely diffusible form of PDGF-A, and one long, matrix 
associated form (Betsholtz et al., 1986; Bonthron et al., 1988; Rorsman et al., 
1988). The short form of PDGF-A almost always predominates, but the long 
form has been found in most cell lines and tissues expressing PDGF (Matoskova 
et al., 1989). The significance of this alternate transcript is illustrated by the fact 
that the basic stretch of amino acids in PDGF-A is highly evolutionary conserved 
between Xenopus Laevi (Mercola et al., 1988), mouse and man (Rorsman and 
Betsholtz, 1992), and that it is highly similar not only to the corresponding 
sequence in PDGF-B, but also to a differentially spliced exon in Vascular 
Endothelial Growth Factor (VEGF) (Betsholtz et al., 1990) and Placenta 
Growth Factor (PlGF) (Maglione et al., 1993). 
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PDGF-C and -D do not contain the C-terminal retention motif found in 
PDGF-A and -B. However, CUB-domains can be involved in protein-protein 
and protein-carbohydrate interactions (Kristiansen et al., 1999; Nakamura et al., 
1998), and we have hypothesized that this motif may be important for binding 
to the pericellular matrix (Paper III). 
 
PDGF receptors 
PDGFs exert their effects by binding to two structurally related receptor tyrosine 
kinases, PDGFR-α and PDGFR-β, which are transmembrane proteins with 
molecular sizes of 170 and 180 kDa after glycosylation (Claesson-Welsh et al., 
1989; Matsui et al., 1989a; Yarden et al., 1986). 
The extracellular part of each receptor contains five immunoglobulin-like (Ig) 
domains. An intracellular tyrosine kinase domain with a characteristic insertion 
puts the PDGF receptors in a larger family of “split-kinase RTKs” (Manning et 
al., 2002a), together with KIT, CSF1R/FMS and FLT3 that all have five Ig-
domains. The closely related VEGFR1-3 contain seven Ig-domains. The human 
genome sequence reveals that all these eight genes map to three of the four 
paraHOX clusters, and probably derive from local cisduplications and 
transduplications of the single ancestral paraHOX locus (Manning et al., 2002b). 
Finally, FGFR1-4 are more distantly related split-kinase RTKs with three 
extracellular Ig-domains. 
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Figure 4. PDGF ligand / receptor specificities in vitro. 
 
 
The PDGF receptors, as all other split-kinase RTKs, are monomers in the cell 
membrane. Because of the dimeric nature of the PDGF ligands, they bind two 
receptors simultaneously, which leads to receptor dimerization. PDGF-A, -B and 
-C are high affinity ligands for PDGFRα, while PDGF-B and -D are PDGFRβ 
agonists in vitro (Paper III; Bergsten et al., 2001; Matsui et al., 1989a). 
Somewhat surprisingly, both PDGF-CC and PDGF-DD seem to be able to 
induce the PDGFRαβ heterodimer (Gilbertson et al., 2001; LaRochelle et al., 
2001), even though they only bind to one of the monomers with high affinity. 
This leads to the ligand/receptor specificities portrayed in Fig.4. 
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D
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Activation of PDGF receptors induces a variety of cellular responses, such as 
proliferation, chemotaxis and antiapoptotic signals (reviewed in Heldin et al., 
1998; Heldin and Westermark, 1999). The different receptor dimers transmit 
partially overlapping, but also partly specific signals. Whereas both receptors 
direct cytoskeletal rearrangements, only PDGFRβ mediates formation of circular 
actin ruffles at the dorsal surface of porcine aortic endothelial cells (Eriksson et 
al., 1992). Additionally, PDGFRβ can promote chemotaxis in certain cell types, 
such as vascular smooth muscle cells. PDGFRα inhibits migration in these cell 
types, but can stimulate chemotaxis in other cells (Hosang et al., 1989; Koyama 
et al., 1992; Matsui et al., 1989b; Osornio-Vargas et al., 1996; Shure et al., 
1992; Siegbahn et al., 1990). PDGFRβ also promotes release of intracellular 
calcium more efficiently than PDGFRα (Diliberto et al., 1992). 
From these in vitro studies, it would thus seem that PDGFRβ is able to direct 
certain cellular functions that the PDGFα receptor cannot. Furthermore, 
PDGF-AB gives a stronger proliferative and migratory effect on cells that express 
both PDGF receptors, indicating that the PDGFRαβ heterodimer may possess 
unique signaling properties (Heidaran et al., 1991; Rupp et al., 1994). 
 
Ligand-induced dimerization of the PDGF receptors allows for 
autophosphorylation of tyrosine residues in trans between the two receptor 
monomers. The three outermost Ig loops of the receptors are responsible for 
ligand binding, with loop two being the most important. The dimeric complex is 
further stabilized by direct interaction between the receptors (reviewed in Heldin 
et al., 1998). 
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Following autophosphorylation, downstream signaling molecules will attach 
to phosphotyrosines in a sequence-specific manner. In the PDGF receptors this 
is accomplished by Src homology 2 (SH2) domain-containing proteins, 
including phosphatidylinositol 3’ kinase (PI3K), phospholipase C-γ (PLC-γ), src 
family tyrosine kinases, signal transducers and activators of transcription (Stats), 
SHP2 tyrosine phosphatase, and adaptor molecules, for instance Grb2/Sos1 and 
Nck. 
Most such molecules can bind to both PDGF receptors, but there are 
exceptions. The GTPase-activating protein for Ras (Ras-GAP) only binds to 
PDGFRβ, and the adaptor molecule Crk is specific for PDGFRα (Heldin et al., 
1998). 
 
The binding of more than 10 SH2 domain-containing signal transduction 
molecules to the receptor leads to the activation of a complex network of 
interacting intracellular signaling pathways. A great effort has been put down in 
the last decades to map the individual signal transduction conduits in detail, with 
the assumption being that intrinsic differences in the signaling cascades would 
lead to specific cellular responses (reviewed in Hunter, 2000; Schlessinger, 
2000). 
Later studies have challenged this hypothesis, and indicated that activation of 
RTKs rather provides a general “go” signal that is interpreted differently in 
diverse cellular contexts. For instance, mutations of distinct tyrosine residues in 
PDGFRβ demonstrated that various pathways have broadly overlapping effects 
on the induction of immediate early genes in fibroblasts, and even that FGF and 
PDGF activation of the same celltype leads to highly similar responses 
(Fambrough et al., 1999). Furthermore, three studies on cell-fate decision in 
Drosophila showed that marker gene expression was dependent not on specific 
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intracellular signals, but instead by integration of a generic RTK signal with cell-
specific transcription factors (Simon, 2000). 
The specificity of PDGF receptor signaling pathways was recently examined 
by gene targeting in mice (Heuchel et al., 1999; Klinghoffer et al., 2002; 
Klinghoffer et al., 2001; Tallquist et al., 2000a). These studies, which will be 
discussed further in the next chapter, suggest both overlapping and specific 
functions for RTK-activated signaling pathways.  
 
Expression of PDGF and PDGF receptors 
Expression of platelet-derived growth factor and PDGF receptors has been 
detected in a wide variety of cell types (reviewed in Heldin and Westermark, 
1999). Many of those studies should be interpreted with caution, however, 
because the fact that a cell type is able to produce a factor when in culture not 
necessarily implies an important physiological function. 
 
In adult humans, PDGF is expressed at very low levels in most tissues (Raines 
and Ross, 1993), and it is possible that the role of PDGF in most aspects of 
normal adult physiology is negligible. An exception to this may be the central 
nervous system. Here, a neuroregulatory function for PDGF has been suggested, 
because high levels of PDGF and PDGF receptor expression has been detected in 
the normal adult mammalian brain (Sasahara et al., 1991; Yeh et al., 1991). The 
highest levels of PDGF-B and PDGFRα were found in the olfactory bulb, an 
interesting observation since replacement of olfactory neurons is known to take 
place throughout adult life (Lee et al., 1990; Sasahara et al., 1992). 
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PDGF might also have a role in the regulation of interstitial fluid pressure 
(Rodt et al., 1996), possibly through PI3K mediated activation of the collagen-
binding integrin α2β1 (Heuchel et al., 1999). 
Imatinib is a potent inhibitor of PDGFR signaling that has recently been used in 
clinical trials as a treatment for chronic myelogenous leukemia. The relatively 
mild adverse effects that have been reported when using this drug support the 
notion that PDGF signaling is of less importance in adult physiology. 
Interestingly, one of the more common side effects is oedema, which could be 
due to loss of PDGF-dependent regulation of interstitial fluid pressure 
(Esmaeli et al., 2002). 
 
Whereas the importance of PDGF in adult physiology is debatable, a clearer 
function is seen in pathophysiological situations. As a common theme, PDGF 
upregulation is coupled to fibroproliferative responses. Examples of this include 
wound healing, atherosclerosis, glomerulonephritis, pulmonary fibrosis, 
rheumatoid arthritis and malignant tumors. In most cases, PDGF from platelets, 
macrophages, epithelial and endothelial cells acts as a paracrine growth factor for 
PDGF receptor positive fibroblasts and smooth muscle cells. In certain tumors, 
however, autocrine PDGF receptor activation is probably a rate-limiting event 
(reviewed in Heldin and Westermark, 1999). 
 
PDGF is also essential for embryonic development. In the early preimplantation 
embryo, PDGF-A and PDGFRα are expressed in the same cells, suggesting 
autocrine signaling. Expression studies in later developmental stages have 
demonstrated that high levels of the PDGF receptors mainly are found in 
mesenchymal and certain neuroectodermal cells, while the ligands are present in 
adjacent epithelial and endothelial cells. Notable exceptions to these patterns are 
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the presence of PDGF-A and -C in the myotome and developing muscle, and of 
both PDGF-A, -B and possibly -C in neurons of the central nervous system 
(Aase et al., 2002; Ataliotis and Mercola, 1997; Ding et al., 2000). 
The functional significance of PDGF expression patterns in mouse 
development will be discussed further in the next chapter. 
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Developmental functions of PDGF - lessons from gene 
targeting in mice 
 
“The interpretation, and indeed power, of a screen is observer-dependent. 
There are many possible thematic interpretations of a screen, all woven 
together as in an Escher print or Bach canon, and none is most 'correct', 
although some can provide more experimentally useful predictions than others. 
Even the defined phenotype for any given mutation reflects but one part of the 
function of the gene, the one that happens to be most prominent or fall in the 
field of focus of that particular scientist. Rashomon-like, what is deemed 
distinctive and important by one observer may go unnoticed by another.” 
Mark C. Fishman, The Genomic Cosmos, 
Nature 410, 1033 (2001) 
 
 
Gene targeting - methodological aspects 
Our knowledge of the identity, structure and function of proteins in 
physiological and pathophysiological processes is being driven in an 
unprecedented rate by the application of modern molecular and cell biology 
techniques. While a given gene’s function can be predicted, to some extent, from 
sequence homology analysis, and descriptive studies may show clear 
chronological and spatial evidence of the association of a protein with a 
particular process, it is important to consider that this remains simply an 
association until the target protein is manipulated and the associated process 
critically altered. 
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In their ground-breaking paper from 1944, in which DNA for the first time 
was shown to cause genetic transformation, Avery and co-authors state: 
“Biologists have long attempted by chemical means to induce in higher 
organisms predictable and specific changes which thereafter could be transmitted 
in series as hereditary characters.” (Avery et al., 1944). This dream came true 43 
years later, when work from the groups of Smithies and Capecchi for the first 
time resulted in targeted mutation of a mouse gene at its chromosomal location 
(Doetschman et al., 1987; Thomas and Capecchi, 1987). 
Gene targeting, or homologous recombination in embryonic stem cells (ES 
cells), is now a routine technique that is used to modify the mouse genome at 
any given locus. In addition to the first gene “knock-out” studies, in which a 
gene was completely silenced, it is now possible to create inducible and tissue-
specific alterations, with mutations ranging from a single base pair to 
chromosomal rearrangements (for reviews on gene targeting and inducible 
systems, see Muller, 1999; Nagy, 2000). 
So far, more than 10% of the ~30000 mouse genes have been knocked out. 
This has revolutionized the field of murine genetics and allowed the analysis of 
diverse aspects of gene function in the context of the whole animal. 
 
From a medical point of view, knock-out mice are interesting as models for 
human disease. A recent retrospective study highlights that mouse loss-of-
function phenotypes indeed can correlate well with drug efficacy in humans: 
The 100 best-selling drugs modulate 43 known human drug targets. The 
corresponding mouse genes have been knocked out in 34 instances. Out of these, 
29 show a direct correlation between the resulting phenotype and the therapeutic 
effect of the drug (Zambrowicz and Sands, 2003). It seems obvious that, with 
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well-defined phenotypic screens, prospective gene targeting studies are likely to 
provide an important source of targets for future drug development. 
 
Some potential problems in the generation and analysis of knock-out mice 
should be considered. 
Is the knock-out really a knock-out? If coding segments of the gene still exist 
on the chromosome, truncated versions of the protein could be produced. Even 
if smaller deletions target structurally important parts of the gene, and/or induce 
frame shifts, a mutant polypeptide could still affect other physiological processes 
than the intended. This problem can be avoided by removal of all coding exons, 
but large deletions may also lead to unwanted loss of regulatory regions for other 
genes, or even deletion of entire unidentified genes. 
 
An important consideration is that the introduction of a selection marker, 
usually a neomycin resistance gene (Neo) under the phosphoglycerate kinase 
(PGK) promoter, could affect gene expression. Several reports have shown that 
the strong promoter in the selection cassette interferes with the neighboring 
gene, creating a hypomorphic allele (Muller, 1999). There are exceptions, 
however, and each case should be judged individually. In one report, 
introduction of a Neo gene in the mouse Jλ1 region lead to a drastic increase in 
Jλ1 transcription. When the Neo cassette was enzymatically removed with 
Cre recombinase, the remaining short loxP sequence was shown to act as a 
strong repressor of transcription, rendering a hypomorphic Jλ1 allele 
(Sun and Storb, 2001). 
 
The interpretation of a phenotype is often complicated by functional 
redundancies at several levels. Knock-out mice may display diverse phenotypes 
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when studied on different genetic backgrounds. The results are often clearer 
when mutations are maintained in congenic strains rather than outbred mice, 
since the effect of multiple modifier loci can be controlled. On the other hand, 
important phenotypes may be absent in certain strains, and the best strategy is 
often to place a mutation in the context of several genetic backgrounds with 
controlled back-crossing. 
Compensation within a gene family is also a common phenomenon. For 
example, PDGF-A, -B, -C (and to some extent -D) can all activate PDGFRα. 
On sites where the ligands are co-expressed, it is conceivable that necessary levels 
of receptor activation can be maintained even after inactivation of one PDGF 
gene. 
 
Platelet-derived growth factor mutants 
Mice harboring targeted deletions of all PDGF ligands and receptors except 
PDGF-D have been generated (Paper I; Paper IV; Leveen et al., 1994; Soriano, 
1994; Soriano, 1997), and all heterozygous mutants are healthy and fertile. In 
the following, unless explicitly stated otherwise, only the phenotypes of 
homozygous mutant animals will be described. 
Complex phenotypic alterations in PDGF-A knockout mice 
PDGF-A is essential for postnatal survival. In a mixed genetic background, 
PDGF-A knockout (PDGF-A-/-) mice either die before E10 or survive until 
birth (Paper I). 
The early lethal phenotype appears to be more common on a C57Bl/B6 
background, and consists of growth retardation with increased apoptosis in 
mesenchymal structures, branchial arch hypotrophy, mild myotome patterning 
defects and an undulated neural tube (M. Hellström, unpublished observations). 
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Postnatally surviving PDGF-A-/- mice die within the first few weeks and display 
several developmental defects. The probable cause of death is a complete lack of 
alveolar septation in the lungs with concomitant pneumothorax and atelektasis. 
The alveogenesis defect is coupled to reduced elastin deposition and a loss of α-
smooth muscle actin (ASMA) positive interstitial cells, normally located at the 
tip of the alveolar septa (Paper I). These cells have been described as both 
“myofibroblasts” (Oldmixon et al., 2001) and “smooth muscle cells” (Kapanci et 
al., 1974), but there is a clear consensus about the fact that they are 
mesenchymal cells with a hefty contractile machinery. 
At embryonic day 14.5 (E14.5), PDGF-A is expressed by the pulmonary 
epithelium, while PDGFRα expression is restricted to the adjacent mesenchyme. 
At E18.5, PDGF-A expression could no longer be detected, and PDGFRα 
positive cells were scattered in the lung mesenchyme. This scattered 
subpopulation is missing in PDGF-A deficient mice, and we propose that these 
cells are the precursors of alveolar myofibroblasts. Furthermore, it appears that 
the alveolar myofibroblast has a crucial role in alveolar formation and elastin 
deposition in the lung (Paper I). 
In a follow-up study, Lindahl and co-workers attempted to find overlapping 
markers to prove that the scattered PDGFRα positive cells indeed are 
progenitors to the alveolar myofibroblasts. This failed, but they showed that 
these cells probably represent the same cell lineage as tropoelastin positive cells 
seen at postnatal day 4 (P4), after PDFGRα has been downregulated but before 
ASMA expression can be detected, and that the third phase of elastin deposition 
in the lungs was absent in PDGF-A-/- mice. Finally, the absence of the scattered 
PDGFRα positive population was attributed to lack of multiplication and distal 
spreading of PDGFRα positive cells between E16.5 and E17.5, probably because 
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of reduced proliferation and possibly migration. No increase in apoptosis was 
seen in PDGF-A negative lungs (Lindahl et al., 1997b). 
 
PDGF-AA, expressed by neurons and glial cells, is a potent mitogen for 
PDGFRα positive O2A oligodendrocyte progenitors in vitro. In PDGF-A 
deficient spinal cords, the proliferation of O2A progenitors was severely reduced 
(Calver et al., 1998), and mutant mice displayed defective oligodendrogenesis 
with a dysmyelinating phenotype (Fruttiger et al., 1999). 
By examining O2A progenitor cell number in wildtype mice, in transgenic 
animals overexpressing PDGF-A at various levels, and in heterozygote and 
homozygote PDGF-A knockout mutants, William Richardson and colleagues 
have provided some of the most compelling and beautiful arguments regarding 
the in vivo role of PDGF (van Heyningen et al., 2001). When cultured in 
saturating concentrations of PDGF-A, O2A progenitors in dissociated spinal 
cords show an acceleration of the cell cycle independent of their previous rate of 
division, suggesting that cell division normally slows down because of declining 
PDGF concentrations, and not by cell intrinsic mechanisms. 
This hypothesis was further strengthened by the demonstration that O2A 
progenitor cell number is controlled by the supply of PDGF-A in a linear, 
unsaturable fashion, ranging from undetectable levels in PDGF-A knockout 
mice to 10-fold upregulation in quadruple transgenic animals. In the latter case, 
cell number was still increasing but the mice were not viable. 
The authors argue that proliferating O2A cells limit their own proliferation, 
the mechanism being that the cells continue to multiply until their consumption 
of PDGF-A matches the paracrine supply of the growth factor (van Heyningen 
et al., 2001). 
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Even though the proliferation of O2A progenitors differ in the various 
mutants, the quantity of postmitotic oligodendrocytes is not affected in 
heterozygous PDGF-A knockouts or overexpressing transgenic mice. This 
indicates that while the number of O2A progenitors is controlled by PDGF-A, 
the number of mature oligodendrocytes is controlled by other mechanisms, 
probably axon-derived survival factors, since increased apoptosis of oligo-
dendrocytes was observed in PDGF-A transgenic mice (Calver et al., 1998). 
 
Three other described phenotypes in PDGF-A knockout mice draw attention to 
the theme of paracrine epithelial-mesenchymal signaling by PDGF-A over 
PDGFRα in mouse development. 
Male PDGF-A deficient mice display spermatogenic arrest, likely secondary to 
a diminished number of Leydig cells and associated reduction of testosterone 
levels. In the developing testis, tubular epithelial cells express PDGF-A and 
interstitial mesenchymal cells, which are putative Leydig cell progenitors, express 
PDGFRα (Gnessi et al., 2000). 
In the skin, PDGF-A is expressed in the developing hair follicle epithelium 
and epidermis, and PDGFRα expression is detected in the underlying 
mesenchyme. Consequently, PDGF-A deficient mice show mesenchymal defects 
in the dermis and abnormal hair development with misshapen hair follicles 
(Karlsson et al., 1999). 
A similar expression pattern is seen in the developing gut, and PDGF-A 
knockouts display abnormal gastrointestinal development with dysmorpho-
genesis of villi that is most pronounced in the upper small intestine. PDGF-A 
signaling appears to drive the proliferation of PDGFRα positive progenitor cells 
that are important for the formation of a tight cluster of mesenchymal cells 
adjacent to the growing villus (Karlsson et al., 2000). 
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In both the skin and the gut, proliferation defects were demonstrated by 
reduced BrdU labeling of mesenchymal cells in PDGF-A negative mice. Signs of 
premature differentiation were also seen in the gut, in which ASMA expression 
was detected at earlier timepoints in the mutants than in wildtype littermates. 
The importance of extracellular retention of PDGF-A 
As described in the previous chapter, PDGF-A exists in two isoforms due to 
alternative splicing of the sixth exon. When present, the exon-six-encoded 
sequence mediates binding to the pericellular matrix. We generated mice with a 
targeted deletion of the sixth exon splice acceptor in PDGF-A, so that only the 
short, freely diffusible form of PDGF-A was produced from the recombinant 
allele (Paper V). 
PDGF-A retention deficient mice (PDGF-Aret) appear to be healthy and 
normal. Since we had reason to suspect that PDGF-C might compensate for loss 
of PDGF-A under certain conditions (see below), we bred PDGF-Aret mice 
against PDGF-C knockouts. Double mutants recapitulated the gastrointestinal 
phenotype found in PDGF-A negative mice. This was in agreement with the 
finding of relatively high expression levels of the long form of PDGF-A in the 
developing gut. Furthermore, the spina bifida sometimes seen in PDGF-C 
deficient mice (Paper IV) was severely aggravated by the addition of the PDGF-
Aret allele, indicating that extracellular-matrix bound PDGF-A may contribute 
to neural arch formation. 
Theoretically, retention of PDGF-A could be important for guided cell 
migration, for eliciting isoform-specific signals or for guaranteeing adequate local 
concentration of the growth factor. We hypothesize that the latter scenario is the 
most probable, and the observed phenotypes are the result of a functionally 
hypomorph situation (discussed in detail in Paper V). 
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Mice deficient for PDGF-B display cardiac and vascular defects 
PDGF-B deficient mice die between E16 and E18 due to vascular defects 
(Leveen et al., 1994). During mouse development, PDGF-B is expressed mainly 
by megakaryocytes and vascular endothelium (Lindahl et al., 1997a). All 
observed phenotypes in PDGF-B knockouts seem to be caused by defective 
recruitment of PDGFRβ positive vascular smooth muscle and pericyte 
progenitors. 
Reduced proliferation and possibly migration of these cell populations in 
PDGF-B deficient mice leads to macroscopically apparent bleedings and edema, 
coupled to arterial SMC hypotrophy and reduced number of pericytes in smaller 
vessels. Pericytes are probably important for the mechanical stability of the 
microvessel wall, since ruptured capillary microaneurysms was a common 
phenomenon in the PDGF-B knockouts (Lindahl et al., 1997a). 
 
In the kidney and the placenta, specialized pericytes fail to develop. PDGFRβ 
positive kidney mesangial cells are responsible for establishing the structural 
integrity of the glomerular tuft, and in PDGF-B knockouts these cells are not 
properly recruited, leading to the formation of a primitive balloon-like structure 
(Leveen et al., 1994; Lindahl et al., 1998). An analogous picture is seen in the 
developing placenta (Ohlsson et al., 1999).  
Pericyte deficiency was most pronounced in brown adipose tissue, brain and 
heart, where cardiac muscle hypotrophy was evident. In other tissues, such as the 
skin and gastrointestinal tract, the number of pericytes was normal. These sites 
are obviously less dependent on PDGF-B mediated expansion of pericyte 
progenitors, either because other growth factors can substitute for PDGF-B, or 
possibly because intrinsic differences exist in a tissue’s ability to form 
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new vascular SMC/pericyte progenitors from competent mesenchyme 
(Hellstrom et al., 1999). 
Cell-type-specific ablation of PDGF-B by the creation of chimeric mice 
and conditional gene targeting  
To elucidate the physiological role of PDGF-B from different cellular sources, 
mice with cell-specific targeted deletions of PDGF-B have been generated by two 
different approaches. 
 
First, using the Cre/loxP system, PDGF-B was inactivated in Tie1-expressing 
endothelium and Cam kinase-expressing neurons. 
Depending on the efficiency of Cre-mediated recombination, mice with 
endothelium specific ablation of PDGF-B displayed all phenotypes observed in 
the PDGF-B knockout. This suggests that the endothelium is the physiologically 
relevant source of PDGF-B in mouse development. Substantial rescue of several 
of the phenotypes was seen postnatally. A possible explanation for this finding is 
that PDGF-B may be rate-limiting only during a certain developmental period, 
and that other factors then can compensate for the loss of PDGF-B 
(M. Bjarnegård, unpublished results). Since these mice are viable, it was possible 
to assess retinal angiogenesis. Here, the failure to recruit pericytes lead to 
proliferative retinopathy, an interesting observation since analogies can be drawn 
to ophtalmological complications in human diabetes (Enge et al., 2002). 
Studies on mice with neuron-specific deletion of PDGF-B failed to 
demonstrate any abnormalities in CNS development or astroglial response to 
injury, questioning the importance of PDGF-B expression in this cell population 
(Enge et al., 2003). 
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Using another approach, hematopoietic PDGF-B deletion was accomplished by 
lethally irradiating mice, followed by transplantation with PDGF-B deficient 
fetal liver cells that successfully repopulated the bone marrow. Chimeric mice 
lack PDGF-B in all hematopoietic lineages, including platelets and macrophages, 
but have a normal vascular and hematologic phenotype (Kaminski et al., 2001). 
Two follow-up studies on these hematopoietic chimeras challenge old beliefs 
regarding PDGF’s role in pathophysiological situations: 
In wound healing, PDGF-B from hematopoietic sources was not required for 
granulation tissue formation, and surprisingly, vascularization was enhanced in 
the chimeric situation (Buetow et al., 2001). 
In a model of atherosclerosis, hematopoietic chimeras were bred against ApoE 
deficient mice. This study showed that smooth muscle cell accumulation and 
fibrous cap formation in atherosclerotic lesions was delayed, but not prevented, 
in the absence of hematopoietic expression of PDGF-B (Kozaki et al., 2002). 
PDGF-C negative mice show cleft palate and spina bifida 
We recently generated mice deficient for PDGF-C (Paper IV). In an outbred 
genetic background, PDGF-C knockouts are fertile and appear healthy. In 
129S1/Sv mice, however, the absence of PDGF-C leads to early postnatal 
lethality. This is probably due to a complete cleft secondary palate, and an 
associated inability to suckle. PDGF-C is expressed by the medial edge 
epithelium in the developing palate, whilst PDGFRα expression can be detected 
in the underlying mesenchyme. It is likely that PDGF-C drives proliferation of 
this mesenchymal population, but that remains to be proven. 
A proportion of PDGF-C negative mice also display mild spina bifida. In 
general, spina bifida is associated with improper proliferation and differentiation 
of the mesodermal cartilage precursor cells that form the neural arches, but this 
phenotype is poorly characterized in the PDGF-C knockouts. 
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PDGF receptor mutants 
Patterning of the somites and development of neural-crest-derived 
mesenchyme is dependent on PDGFRα 
Mice carrying a targeted deletion of PDGFRα die between E8 and E16. Early 
death seems to be loosely associated to C57Bl/B6 background, and the 
phenotype at this stage resembles the early picture seen in PDGF-A deficient 
mice (M. Hellström, personal communication and Soriano, 1997). 
Older PDGFRα knockouts display incomplete cephalic closure and 
cardiovascular defects (Tallquist and Soriano, 2003), suggesting a role for 
PDGFRα in the development of neural-crest-derived mesenchyme. Skeletal 
abnormalities including fused ribs and vertebrae, bifurcation in ribs, incomplete 
development of the sternum, severe spina bifida and poor development of the 
acromion were frequently seen. This points to a failure of somite patterning. 
Interestingly, myotomal rather than sclerotomal markers were affected in the 
PDGFRα deficient mice (Soriano, 1997), indicating that a primary defect in the 
sclerotome feeds back into the myotome (Tallquist et al., 2000b). 
 
The phenotypes seen in PDGRα mutants are highly similar to those of a 
naturally occurring mouse mutant, Patch, which encompasses the PDGFRα 
locus. Additional features seen in Patch mice, such as a pigmentation defect and 
the presence of an extra rib, indicates that this mutation is multigenic, and it has 
been suggested that the “patchy” pigmentation may be related to misexpression 
of c-KIT (Duttlinger et al., 1995). 
 
Even though the phenotype of PDGFRα deficient mice is more severe than 
those observed in any of the PDGF ligand knockouts, some similarities have 
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been described. Thus, in the developing skin and gut, a virtually identical picture 
to that present in PDGF-A negative mice is seen (Karlsson et al., 1999; Karlsson 
et al., 2000). In PDGFRα negative lungs, no early lung branching defect was 
observed, and this is in agreement with the absence of an early pulmonary 
phenotype in PDGF-A knockouts (Paper II). Since PDGFRα deficient mice die 
before E16, it was not possible to examine any potential effect on alveolar 
formation. 
PDGFR-β negative mice phenocopy PDGF-B knockouts 
Mice lacking PDGFRβ (Soriano, 1994) have not revealed any phenotypical 
differences from PDGF-B deficient mice (Hellstrom et al., 1999). This 
emphasizes the importance of PDGF-B/PDGFRβ signaling in mouse 
development, but also questions the relevance of other ligand/receptor 
interactions. If any functions exist for PDGF-DD in signaling over PDGFRββ, 
or for PDGF-AB and PDGF-CC in signaling over PDGFRαβ, this remains to 
be shown. PDGF-B may not be a physiologically important ligand for PDGFRα 
simply because the expression patterns of the two genes are physically separate 
during murine embryogenesis. 
Cell autonomous requirement for PDGF receptors revealed by 
chimeric analyses 
Mouse chimeras have been used to let cells harboring a targeted gene deletion 
compete with wildtype cells for representation in different cell lineages. If a 
competitive disadvantage is observed for the knockout cells, this indicates an 
intrinsic, cell autonomous, role for the targeted gene in that particular tissue. 
Using this methodology, chimeric analysis showed a selection against 
PDGFRα deficient cells in all tissues affected in the knockout. Additionally, 
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strong selection for PDGFRα bearing cells was seen in the limb bud, even 
though no limb development defects have been described in PDGFRα negative 
mice (Tallquist and Soriano, 2003). This suggests a redundant function for 
PDGFRα in the limb bud progress zone. 
A similar competition assay with wildtype and PDGFRβ negative cells 
revealed a role for PDGFRβ not only in vascular SMC lineages, but also in 
gastrointestinal smooth muscle layers as well as cardiac and skeletal muscle 
(Crosby et al., 1998). In a later study, the selection against PDGFRβ deficient 
cells in striated muscle was not evident in high degree chimeras, indicating that 
this competitive disadvantage is rather weak (Tallquist et al., 2000a). 
When the degree of chimerism is not too high, chimeric mice are viable, and 
PDGFRβ chimeras have been used to identify cell autonomous requirements for 
PDGFRβ in wound healing (Crosby et al., 1999). Here, it was demonstrated 
that fibroblasts and endothelial cells (or endothelial cell progenitors) require 
PDGFRβ to participate in reactive connective tissue formation. 
Selective mutations in PDGF receptors suggest both overlapping and 
specific functions for RTK-activated signaling pathways 
As discussed in the previous chapter, activation of the PDGF receptors by ligand 
binding induces complex intracellular signaling networks. To try to elucidate if 
the observed functional specificities of the two PDGF receptors in vivo depend 
mainly on differences in spatio-temporal expression patterns or divergent 
mechanisms of signal transduction, Philippe Soriano and co-workers have 
generated several lines of gene targeted mice with specific mutations in the 
PDGFR signaling domains. 
Two lines of knockin mice where the intracellular signaling domains of one 
PDGF receptor was replaced by those from the other PDGFR demonstrates that 
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the two receptors mediate largely overlapping functions. Mice homozygous for 
each replacement mutation were completely viable and fertile. However, when 
stressing the system further, a requirement for PDGFRβ-type signaling is 
revealed: Heterozygous mice, carrying one PDGFRβ knockout allele and one 
allele where the intracellular PDGFRβ-domain was replaced with that from 
PDGFRα, display retinopathy and kidney defects comparable to those seen in 
PDGF-B deficient mice (Klinghoffer et al., 2001). The authors argue that this 
may be due to a decreased capacity to sustain MAP kinase activation, but it is 
also possible that the observed phenotype simply is an effect of a hypomorphic 
PDGFRβ allele. 
Redundancy has also been demonstrated on the level of individual signaling 
pathways. Several cellular effects, including chemotaxis and actin cytoskeleton 
rearrangements, have been implicated to be dependent on activation of PI3 
kinase signaling (reviewed in Heldin et al., 1998). However, mice with a 
PDGFRβ mutant for PI3K binding develop normally, indicating functional 
compensation in vivo (Heuchel et al., 1999). A possible requirement for 
PDGFRβ signaling via PI3K was demonstrated in fluid pressure homeostasis: 
After treatment with a mast cell degranulating agent, mutant mice were unable 
to restore interstitial pressure in response to an injection of PDGF-BB. 
Phospholipase C γ activation has been suggested to be redundant to PI3K 
signaling, and for this reason mice were generated that lacked the ability to 
activate either of these pathways following PDGFRβ stimulation. Even more 
surprisingly than in the previous study, PLCγ/PI3K mutant mice have no 
distinguishable phenotype, even though migration and proliferation of mutant 
cells were substantially affected in vitro (Tallquist et al., 2000a). Loss of mutant 
mesangial cells in experimentally induced glomerulonephritis also indicated 
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important functions for PDGFRβ mediated activation of PLCγ/PI3K in 
pathophysiological situations. 
In the analysis of an allelic series at the PDGFRα locus, it was demonstrated 
that while mutations in the binding sites for either Src family kinases or PI3K 
lead to defective oligodendrocyte development, only PI3K site mutations affected 
skeletal development (Klinghoffer et al., 2002). Notably, PDGFRα/PI3K 
signaling mutants also recapitulated the alveogenesis defect seen in PDGF-A 
deficient mice (Paper I), and the cleft palate seen in PDGF-C knockouts (Paper 
IV). The observed phenotype in the PI3K mutant was not aggravated with the 
addition of additional tyrosine-to-phenylalanine mutations, suggesting that PI3K 
is the major effector of PDGFRα signaling in mouse development. 
If this is true, why is there a phenotypic difference between PDGFRα 
deficient mice and PDGFRα/PI3K signaling mutants? One explanation could be 
that a mutant PDGFRα would still be able to activate PI3K by means of a 
heterodimeric receptor complex. Consistent with this idea, embryos with 
mutations in the PI3K binding sites of both PDGF receptors recapitulate the 
PDGFRα knockout phenotype (Klinghoffer et al., 2002). 
 
The abovementioned studies demonstrate both significant functional redun-
dancy between different PDGF receptor mediated signaling pathways, and that 
distinguishable physiological effects can be attributed to specific members of this 
network. It is still unclear, however, if these results mainly reflect a quantitative 
difference in intracellular signal strength and duration, or if a true qualitative 
diversity in the ability to elicit specific cellular responses exists. 
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The generation of PDGF-A / PDGF-C double deficient mice 
provides an important piece in the PDGF puzzle 
Even though signaling via the two PDGF receptors elicits largely redundant 
biochemical responses, targeted deletion of PDGFRα and PDGFRβ has 
demonstrated highly distinct functions in mouse development. It is tempting to 
suggest that this functional diversity mainly is caused by different gene 
expression patterns and ligand binding specificities, rather than differences in 
intracellular signaling. Consistent with this idea, PDGF-B knockouts and 
PDGFRβ deficient mice are phenotypically indistinguishable (Leveen et al., 
1994; Soriano, 1994). 
PDGFRα negative mice display a phenotype that is more severe than any 
single PDGF ligand knockout, and not even PDGF-A/B double deficient mice 
recapitulated the PDGFRα phenotype (M. Hellström, unpublished observa-
tions). Based on ligand binding studies and expression patterns (Paper III; Aase 
et al., 2002; Ding et al., 2000), we hypothesized that the PDGFRα ligands 
PDGF-A and -C may have overlapping functions in mouse development. 
To test this hypothesis, we generated mice that lacked the ability to produce 
both PDGF-A and PDGF-C. These double deficient mice reproduced 
all described PDGFRα phenotypes, including cleft face, cardiac and skeletal 
abnormalities and loss of interstitial mesenchyme in the kidney cortex 
(Paper IV). 
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Critical PDGF ligand/receptor specificities in mouse 
development 
Taken together, the combined results from gene targeting studies in mice suggest 
that PDGF-AA and PDGF-CC are the essential ligands for PDGFRαα in mouse 
development, whereas PDGF-BB is the principal dimeric ligand for PDGFRββ 
(Fig. 5). The possible functions of other ligand/receptor combinations in mouse 
embryogenesis appear to be redundant, but that does not exclude important roles 
in adult physiology and pathophysiology. 
 
 
 
 
Figure 5. Critical PDGF ligand / receptor specificities in mouse development. 
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Analogous functions for PDGFs and their target cells 
It is evident from the cited reports that platelet-derived growth factors are 
important for the development of specific mesenchymal and neuroectodermal 
progenitor populations in mouse embryogenesis. In the construction of a 
multicellular organism, coordination of multiple cellular events is required, such 
as proliferation, migration, cytoskeletal reorganization, regulated cell shape, 
extracellular matrix remodeling, cellular adhesion, differentiation and cell 
survival. In vitro studies have suggested that PDGF probably mediates several of 
these functions (Heldin and Westermark, 1999). 
Reduced proliferation is the only clearly demonstrated cellular effect in mice 
with targeted PDGF family alleles, as demonstrated by BrdU labeling 
experiments in PDGF-A knockouts (Karlsson et al., 1999; Karlsson et al., 2000; 
van Heyningen et al., 2001), as well as PDGF-B and PDGFRβ deficient 
mutants (Hellstrom et al., 1999). 
Increased apoptosis in the cranial neural crest was reported in PDGFRα 
deficient mice (Soriano, 1997), but a later study by the same author, in which 
PDGFRα had been specifically disrupted in neural crest cells, failed to show any 
effect on either proliferation, migration or apoptosis in this cell population. In 
this study, it was argued that PDGFRα signaling might be important for 
directing matrix deposition, but an alternative explanation is that a proliferation 
defect in only a subset of cells would go undetected (Tallquist and Soriano, 
2003). 
 
Applying William of Ockham’s philosophical razor (“Plurality should not be 
posited without necessity”), a role for PDGF as a mitogen is sufficient to explain 
the phenotypes seen in the mouse mutants. Perceived migratory defects could be 
PDGF-A and -C: Essential Ligands for the PDGF Alpha Receptor 
50 
secondary to failed expansion of progenitor cell populations. This reasoning leads 
to the model depicted in Fig. 6. 
 
 
 
 
Figure 6. Analogous functions for PDGF isoforms. A) PDGF regulates the proliferation of 
PDGFR positive progenitor cells. B) In the absence of PDGF, a failed expansion of 
progenitor cell populations leads to the observed phenotypes. Modified from (Betsholtz et 
al., 2001). 
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Summary and clinical perspective 
 
“Hence, we cannot categorically deny that perhaps we may be able to grind 
genes in a mortar and cook them in a beaker after all.” 
Herbert J. Muller, Variation due to change in the individual gene, 
The American Naturalist 56, 32-50 (1922) 
 
 
In the present study, a novel high affinity ligand for PDGFRα, PDGF-C, was 
described (Paper III). Three new tools for genetic studies were designed: mice 
deficient for PDGF-A (Paper I), PDGF-C (Paper IV), and the retention motif in 
PDGF-A (Paper V). 
I have used these tools to analyze certain functions of PDGF-A and -C in mouse 
embryogenesis. PDGF-A is required for alveolar myofibroblast development and 
alveogenesis (Paper I, II), PDGF-C is essential for closure of the neural arches 
and palate formation (Paper IV), and extracellular retention of PDGF-A is 
important for normal gastrointestinal development (Paper V). 
Interestingly, PDGF-A / PDGF-C double deficient mice recapitulate the pheno-
type of PDGFRα negative mice, indicating that PDGF-AA and -CC are the 
essential ligands for PDGFRαα in mouse development (Paper IV). 
 
As I have described in this thesis, PDGF-A deficient mice have already been used 
by others to demonstrate important functions for PDGF-A in the development 
of the CNS, skin, gut and testis. The three lines of mice will hopefully be useful 
tools also in future research. Since PDGF-A retention deficient mice are viable, 
they can be studied in pathophysiological contexts to elucidate the importance of 
extracellular retention of PDGF-A in wound healing and other processes. 
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The phenotypes reported in this study suggest that signaling over the receptor 
tyrosine kinase PDGFRα regulates mesenchymal progenitor cell populations that 
are important for normal development of the lung, the intestine, the palate and 
in closure of the neural tube. It is tempting to speculate that modulation of 
PDGF activity may be a causative factor in certain diseases affecting these organs. 
Furthermore, stimulation or inhibition of PDGF signaling could prove to be 
successful therapeutic approaches in the treatment of such conditions. 
To my knowledge, no direct evidence has been presented that implicates 
PDGF in human cleft palate syndromes, but it is likely that future studies will 
link a subgroup of orofacial clefts to disturbed PDGF signaling. 
In agreement with our mouse knockout data, specific combinations of human 
PDGFRα promoter haplotypes have been shown to correlate to neural tube 
defects including spina bifida (Joosten et al., 2001). 
A role for PDGFRα in the development of gastrointestinal stromal tumors 
(GISTs) was recently shown. A subgroup of c-KIT negative GISTs were found 
to contain activating mutations in PDGFRα. There is reason to believe that 
these tumors will respond well to treatment with imatinib, in an analogous 
fashion to c-KIT positive GISTs (Heinrich et al., 2003). 
 
In the lung, upregulation of PDGF ligands and PDGFRα is seen in 
pulmonary fibrosis (reviewed in Lasky and Brody, 2000), demonstrating the 
importance of PDGF signaling for mesenchymal cells in the lung. 
The highly specific alveogenesis defect found in PDGF-A deficient mice 
makes it possible to hypothesize that regeneration of alveoli in the adult human 
might be feasible if PDGF-responsive mesenchymal progenitors still exist in the 
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lung. This scenario would be of major interest in the treatment of emphysema, 
one of the most common causes of death in the Western world. 
Indeed, treatment with retinoic acid was shown to abrogate elastase-induced 
emphysema in rats (Massaro and Massaro, 1997), and it has been suggested that 
this effect at least to some extent is mediated by PDGF (Liebeskind et al., 2000). 
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